TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Lucentis in Advanced Macular Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects will be eligible if the following criteria are met:~* Ability to provide written informed consent and comply with study assessments for the full duration of the study.~* Age \> 50 years.~* Low vision AMD patients with a VA of 20/400 or worse.~* Evidence of active exudation as manifested by subretinal or intraretinal fluid on OCT or fresh appearing subretinal hemorrhage on fundus examination.~Exclusion Criteria:~Subjects who meet any of the following criteria will be excluded from this study:~* Pregnancy (positive pregnancy test) or lactation.~* Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.~* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.~* Participation in another simultaneous medical investigation or trial.~* Concurrent eye disease in the study eye that could compromise visual acuity (e.g., diabetic retinopathy, advanced glaucoma).

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ranibizumab Group 1 (Type: OTHER): Group 1: 3 monthly injections of 0.5mg then prn
- ranibizumab Group 2 (Type: OTHER): Group 2: 6 monthly injections of 0.5 mg then prn

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal status defined as history of at least 12 months without spontaneous menstrual bleeding or a documented hysterectomy and bilateral salpingo oophorectomy~* Breast density greater than 25%~* No hormone replacement therapy for at least six months prior to entry into this study~* Non-smokers.~Exclusion Criteria:~* History of stroke, pulmonary embolism or deep vein thrombosis~* History of atherosclerotic heart disease~* Presence of any known hypercoagulable state either congenital (e.g., protein S deficiency) or acquired (e.g., corticosteroid treatment)~* Diabetes mellitus~* Uncontrolled hypertension (BP ≥140/90)~* Presence of a psychiatric condition that would interfere with adherence to the protocol.

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Group 1: Control (Type: NO_INTERVENTION): Control, no intervention
- Group 2: Raloxifene 60 Mg Oral Tablet (Type: EXPERIMENTAL): Raloxifene 60 mg Orally Daily
- Group 3: Raloxifene 30 Mg Oral Tablet (Type: EXPERIMENTAL): Raloxifene 30 mg Orally Daily
- Group 4: Lovaza 4 gm oral (Type: EXPERIMENTAL): Lovaza 4 gm/day Orally with Meals
- Group 5: Lovaza 4gm & Raloxifene 30mg (Type: EXPERIMENTAL): Lovaza 4 gm/day oral capsule with meals plus Raloxifene 30 mg oral tablet daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Haploidentical transplant recipients~* Informed consent signature~* Previous diagnosis of any neoplastic, metabolic or autoimmune disease~Exclusion Criteria:~* History of immune deficiency virus infection~* Hepatitis C or B virus infection~* Documented bacterial of fungal infection prior to tocilizumab infusion~* Previous use of tocilizumab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab 4 mg/kg (Type: EXPERIMENTAL): Tocilizumab 4 mg/kg IV single dose day -1 prior to haploidentical transplantation
- Tocilizumab 8 mg/kg (Type: ACTIVE_COMPARATOR): Tocilizumab 8 mg/kg IV single dose day -1 prior to haploidentical transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male \& female subjects aged 13-17 years, inclusive at time of consent and at baseline visit, with a primary diagnosis of schizophrenia as defined by DSM-5 criteria and confirmed by K-SADS-PL and a history of the illness for at least 6 months prior to screening.~* PANSS score \>= 80, inclusive, at screening and baseline~Exclusion Criteria:~* Subjects with a DSM-5 diagnosis other than schizophrenia that has been the primary focus of treatment within 3 months of screening.~* Subjects with a clinical presentation or history that is consistent with delirium, dementia, amnesia or other cognitive disorders~* Subjects who have been hospitalized \> 21 days for a current exacerbation of schizophrenia at the time of baseline.~* Any neurological disorder other than Tourette's Syndrome~* Subjects at significant risk of committing violent acts, serious self-harm or suicide based on history~* Subjects with epilepsy, a history of seizures, severe head trauma or stroke~* Subjects who test positive for drugs of abuse at screening

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole (Type: EXPERIMENTAL): Participants were administered with brexpiprazole oral tablets, daily, dose titrated up to 0.5 mg by Day 4, 1 mg by Day 7, 2 mg by Day 14, then between 2-4 mg after Day 21 up to Week 6 with a 1 mg increase or decrease, based on the Investigator's decision.
- Aripiprazole (Type: ACTIVE_COMPARATOR): Participants were administered with aripiprazole oral tablets, daily, dose titrated up to 2 mg by Day 4, 5 mg by Day 7, 10 mg by Day 14, then 10, 15 or 20 mg after Day 21 up to Week 6 with a 5 mg increase or decrease, based on the Investigator's decision.
- Placebo (Type: PLACEBO_COMPARATOR): Participants were administered with brexpiprazole or aripiprazole matching placebo oral tablets, daily up to Week 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Positive qualitative hepatitis C virus RNA test on two occasions at least 6 months apart~Exclusion Criteria:~* Heart rate \< 50/min,~* Taking amiodarone

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Subjects will receive sofosbuvir and daclatasvir

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists Class 1 or 2 or 3~* \>=18 years of age and of either sex~* scheduled for elective surgical procedure under general anesthesia requiring the use of rocuronium for endotracheal intubation and/or maintenance of neuromuscular blockade in a supine position allowing neuromuscular transmission monitoring and requiring reversal of neuromuscular blockade~* Korean descent born in Korea, never emigrated out of Korea, and have a Korean home address~Exclusion Criteria:~* expected difficult intubation due to anatomic malformations~* expected transfer to intensive care unit after surgery~* neuromuscular disorders affecting neuromuscular blockade~* significant hepatic or renal dysfunction~* require use of pneumatic tourniquet during surgery~* (family) history of malignant hyperthermia~* allergy to cyclodextrins (including sugammadex) or other medication(s) used during general anesthesia; use of toremifene or fusidic acid within 24 hours of study drug administration; contraindication to use of neostigmine or glycopyrrolate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sugammadex (Type: EXPERIMENTAL): None
- Neostigmine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A PK and Salvage Study for Children With HIV-infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed HIV-1 infection by HIV-DNA PCR if \< 18 months old or by HIV ELISA if greater than or equal to 18 months old~2. Subject is less than or equal to 16 years of age at the day of the first dosing.~3. Subject is failing a current NRTI and/or NNRTI containing regimen and is naïve to protease inhibitor containing therapy.~4. Results of biochemistry and haematology testing should be within pre-specified ranges.~5. Subject is able to swallow capsules~6. Caretaker(s) is/are able and willing to sign the Informed Consent Form prior to screening evaluations.~Exclusion Criteria:~1. History of sensitivity/idiosyncrasy to lopinavir, ritonavir, saquinavir or chemically related compounds or excipients which may be employed in the trial.~2. Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.~3. Inability of both child and caregiver(s) to understand the nature and extent of the trial and the procedures required.~4. Use of any of concomitant medication, including the drug listed below, that may interfere with the pharmacokinetics of LPV/r or SQV.~   * NNRTIs~  * Rifampicin~  * Rifabutin~  * Phenobarbital~  * Phenytoine~  * Carbamazepine~  * Dexamethasone~  * Ketoconazole~  * Clarithromycin~5. Pregnancy

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- double-boosted PI (Type: OTHER): double-boosted protease inhibitor combination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Secondary Progressive Multiple Sclerosis (SPMS) diagnosis or with Relapsing Remitting Multiple Sclerosis (RRMS) at risk to develop SPMS (at the discretion of the treating physician)~* on stable MS treatment (Siponimod, dimethylfumarate, glatirameracetate, interferon, teriflunomode) or no current treatment~* no recent treatment changes~Exclusion Criteria:~* prior or current COVID-19 disease~* SARS-CoV-2 antibodies at screening Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Siponimod - continuous (Type: EXPERIMENTAL): Continuous treatment with siponimod (oral, daily, dose depending on CYP2C9 genotype: 2mg or 1 mg) during SARS-CoV-2 mRNA vaccination
- Siponimod- interrupted (Type: EXPERIMENTAL): Siponimod (oral, daily, dose depending on CYP2C9 genotype: 2mg or 1 mg) with treatment interruption (for approx. 2-3 months) for the purpose of a SARS-CoV-2 mRNA vaccination
- Comparator (Type: ACTIVE_COMPARATOR): Baseline DMTs or no treatment during SARS-CoV-2 mRNA vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women \>/= 20 years of age in patients with confirmed acute symptomatic proximal deep vein thrombosis (DVT) without symptomatic pulmonary embolism (PE)~Exclusion Criteria:~* Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT~* More than 48 hours pre-randomization treatment with therapeutic dosages of anti-coagulant treatment or more than a single dose of warfarin from the onset of the current episode of DVT to randomization~* Calculated creatinine clearance (CLCR) \< 30 mL/min~* Subjects with hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk~* Active bleeding or high risk for bleeding contraindicating treatment with unfractioned Heparin (UFH) or warfarin~* Systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: EXPERIMENTAL): None
- Arm 3 (Type: ACTIVE_COMPARATOR): None
- Arm 4 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Peripheral Arterial Hemorrhage With Lava LES (The LAVA Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years;~* Active arterial bleeding in the peripheral vasculature, documented on a suitable imaging study;~* Subject or subject's legally authorized representative is able and authorized to provide written informed consent for the procedure and the study;~* Subject is willing and able to comply with the specified follow-up evaluation schedule;~* Life expectancy \>30 days;~* No prior embolization in the target territory.~Exclusion Criteria:~* Pregnancy or breast feeding. A woman who, in the Investigator's opinion, is of child-bearing potential must have a negative pregnancy test within 7 days before the index procedure;~* Coexisting signs of peritonitis or other active infection;~* Participation in an investigational study of a new drug, biologic or device that has not reached its primary endpoint at the time of study screening;~* Uncorrectable coagulopathies such as thrombocytopenia \<40,000/ μL, international normalization ratio (INR) \>2.0;~* Contraindication to angiography or catheterization, including untreatable allergy to iodinated contrast media;~* Anatomic arterial unsuitability such that, in the Investigator's opinion, the delivery catheter cannot gain access to the selected position for safe and intended embolization;~* Known allergy or other contraindication to any components of Lava LES including dimethyl sulfoxide (DMSO);~* More than 4 Target Lesions will require embolization, in the Investigator's opinion after performance of diagnostic angiography or another suitable imaging study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lava LES (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of FTY720 for Acute Stroke

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80 years~* Clinical presentation of spontaneous intracerebral hemorrhage/ischemic stroke~* MRI/MRA scan compatible with spontaneous intracerebral hemorrhage/ ischemic stroke~* Time to fty720 treatment\< 72 h from symptom onset~* Glasgow Coma Score \>6 on initial presentation or improvement to a Glasgow Coma Score \>6 within the time frame for enrollment.~* Primary supratentorial ICH of ≥5cc and \<30cc~* TOAST: Large-artery atherosclerosis~Exclusion Criteria:~* Patients who will undergo surgical evacuation of intracerebral hemorrhage~* Inability to undergo neuroimaging with Magnetic Resonance~* Glasgow Coma Score \< 6.~* Baseline modified Rankin Scale score \>1~* Primary intraventricular hemorrhage ICH due to coagulopathy (PT \> 15 s or International Normalized Ratio \> 1.3, Partial Thromboplastin Time \> 36) or trauma~* Thrombocytopenia: platelet count \<100 000~* Clinically significant hepatic disease as demonstrated by history, clinical exam (ascites, varices), or laboratory findings (LFTs \>2x normal, coagulopathy as described)~* Comorbid conditions likely to complicate therapy including but not limited to the following: a history of New York Heart Association class II, III, or IV Congestive Heart Failure; end-stage acquired immune deficiency syndrome~* Pregnancy~* Malignancy (history of or active)~* Bradyarrhythmia and Atrioventricular Block~* Concomitant use with antineoplastic,immunosuppressive or immune modulating therapies~* Macular Edema

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Fingolimod (FTY720) group (Type: EXPERIMENTAL): Drug: Fingolimod capsules will be administered as 0.5mg/day over a course of 3 consecutive days after stroke onset.
- Control group (Type: PLACEBO_COMPARATOR): Patients will receive usual care and drug use in hospital.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Genetically confirmed DMD~2. Reduced upper arm strength as measured by the Performance of Upper Limb~3. Reduced ability to walk/run (if ambulatory)~4. Treatment with systemic glucocorticoids for at least 12 months and at a stable dose at least 6 months prior to study participation, except for weight-based or toxicity-related adjustments~5. Current and up-to-date immunizations~Exclusion Criteria:~1. Left ventricular ejection fraction \< 35%~2. BMI \> 45~3. Ambulant if ≥ 18 years of age~4. Exon 44 skip-amenable mutation(s) in the DMD gene~5. Deletion mutation(s) encompassing exons 3-7 of the DMD gene~6. Percent-predicted forced vital capacity (FVC) \< 35%~7. Chronic respiratory disease not related to DMD (for example, asthma, bronchitis, and tuberculosis)~8. History of diabetes requiring treatment with metformin or insulin within 3 months prior to randomization~9. Treatment with an FDA-approved exon skipping therapy for the treatment of DMD if on a stable dose for less than 24 months prior to randomization~10. Treatment with human growth hormone (HGH) within 3 months prior to randomization, unless on a stable dose for at least 24 months prior to randomization~11. Treatment with idebenone within 3 months prior to randomization~12. Treatment with a cell therapy product within 12 months prior to randomization~13. Treatment with an investigational product within 6 months prior to randomization

- Gender: MALE
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CAP-1002 (Type: EXPERIMENTAL): Patients will receive 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months for a total of 4 doses.
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive a placebo solution via intravenous infusion every 3 months for a total of 4 doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and/or Females of non-childbearing potential between 18 and 70 years of age~2. History of mild to moderate hypertension~Exclusion Criteria:~1. Type 1 or 2 diabetes on prescribed medications~2. Secondary, severe, or malignant hypertension~3. History of a significant cardiovascular event within the last 12 months of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- PF-00489791 20 mg titrated to 40 mg (Type: EXPERIMENTAL): None
- PF-00489791 4 mg (Type: EXPERIMENTAL): None
- PF-00489791 10 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete